Drug intelligence / Profile preview

LS-LBP-001

Development stage: Unknown
Lead developer: Shanghai Lishan Biopharmaceutical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

LS-LBP-001 is a live biotherapeutic product (LBP) developed as an oral capsule for the treatment of inflammatory bowel disease, specifically mild to moderate active Crohn's disease. Developed by The Third Xiangya Hospital of Central South University, the therapy consists of live microorganisms intended to modulate the gut microbiota, reduce intestinal inflammation, and restore mucosal homeostasis. It is currently being evaluated in clinical trials in combination with mesalazine to assess its safety, preliminary efficacy, and impact on the gut microbiome in patients with ileal and/or colonic involvement.

Other names: LS-LBP-001 live biotic capsuleLS-LBP001 live biotic capsuleLS-LBP 001 live biotic capsule

Beyond the preview

Go deeper on LS-LBP-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LS-LBP-001.

Explore the full profile